GlassScriptPhysician profile
Nicole Abbot
NPI 1063895522
$1,529.79
in general payments reported to CMS, 2019-2025
20 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $267 · 2022: $136 · 2023: $489 · 2024: $357 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $727.16 | 2021-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $110.46 | 2021-2023 | Wegovy |
| Vanda Pharmaceuticals INC. | $95.64 | 2024-2025 | Hetlioz, Fanapt |
| Boston Scientific Corporation | $64.53 | 2025 | General - Embolics |
| Exact Sciences Corporation | $59.87 | 2023 | Cologuard Collection Kit |
| Alkermes, INC. | $57.20 | 2022-2023 | Aristada, Lybalvi |
| Lilly USA, LLC | $51.20 | 2022-2024 | Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $45.94 | 2023 | Shingrix, Arexvy, Bexsero |
| Amgen INC. | $41.40 | 2022-2023 | Otezla, Repatha |
| Neurocrine Biosciences, INC. | $41.30 | 2025 | |
| Hologic Sales and Service, LLC | $38.55 | 2023 | Aptima, Thinprep 2000 Processor |
| Otsuka America Pharmaceutical, INC. | $34.77 | 2023-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $30.75 | 2021 | |
| Axsome Therapeutics, INC. | $29.07 | 2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $23.99 | 2024 | Austedo Xr |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $20.55 | 2025 | Korlym |
| Vbi Vaccine (Delaware) INC. | $16.80 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.66 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $13.29 | 2023 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Abbot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.